Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mifepristone for Central Serous Chorioretinopathy
NCT02354170Phase 2Completed
- Start
- Jan 2015
- Primary completion
- Apr 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mifepristone in Central Serous Chorioretinopathy (CSCR) (3 arms). Primary endpoint: Resolution of Sub-retinal Fluid at 4 weeks. Started Jan 2015; status: completed.
02
Drugs
mifepristone
03
Conditions
Central Serous Chorioretinopathy (CSCR)
Beyond the preview
Go deeper on NCT02354170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02354170.